Pegfilgrastim Biosimilars Global Market Report 2024

Global Pegfilgrastim Biosimilars Market Report 2024

Pegfilgrastim Biosimilars Global Market Report 2024 – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

Name: Pegfilgrastim Biosimilars Global Market Report 2024
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Pegfilgrastim Biosimilars Global Market Report 2024

Starting Price : $5000.00 $4000.00 | Pages : 250 | Published : March 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Pegfilgrastim Biosimilars Market Definition

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

Pegfilgrastim Biosimilars Market Segmentation

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Global Pegfilgrastim Biosimilars Market Size 2023 to 2028: Graph

Pegfilgrastim Biosimilars Market Size 2024 And Growth Rate

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical r&d expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs.

Pegfilgrastim Biosimilars Market Growth Forecast

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives. Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in r&d activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on m&a growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings.

Book your 30 minutes free consultation with our research experts

Pegfilgrastim Biosimilars Market Driver: Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market.

Pegfilgrastim Biosimilars Market Driver: Increase Incidence Of Cancer Are Anticipated To Fuel The Growth Of The Pegfilgrastim Biosimilars Market

The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Pegfilgrastim biosimilars are used to reduce the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For instance, in 2021, according to The American Cancer Society, a US-based cancer-fighting organization, the new cancer cases in USA increase from 1.8 million in 2020 to 1.9 million in 2021, while cancer-related deaths rose slightly from 606,520 in 2020 to 608,570 in 2021. Therefore, the increased incidence of cancer is driving the pegfilgrastim biosimilars market.

Global Pegfilgrastim Biosimilars Market Major Players

Major companies operating in the pegfilgrastim biosimilars market report are Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd, Mundipharma GmbH, Dr. Reddy’s Laboratories, Pfizer Inc., Emcure Pharmaceuticals, USV Private Limited, Apotex Pty Ltd, Kyowa Kirin Co. Ltd, Qilu Pharmaceutical, Gennova Biopharmaceuticals Limited, Lupin Limited, Coherus Biosciences Inc, Fresenius Kabi, Napp Pharmaceuticals, Boicon, Amega Biotech.

Global Pegfilgrastim Biosimilars Market Restraint: Stringent Fda Approval Process Limits Expansion Of The Pegfilgrastim Biosimilar Market

The FDA's low number of drug approvals hampered the pegfilgrastim biosimilar market during the forecast period. The market currently has only four drugs approved for treatment, thus restricting the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

Global Pegfilgrastim Biosimilars Market Trend: Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market

Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, partnered with Kashiv Biosciences, a US-based integrated biosciences company, to develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA is a preservative-free, clear solution offered in a 6 mg/0.6 mL single-dose prefilled syringe. It’s used to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

Global Pegfilgrastim Biosimilars Market Trend: High Quality Biosimilar For Providing Better Alternative

Major companies operating in the pegfilgrastim biosimilars market are launching high-quality pegfilgrastim biosimilars such as the Stimufend to provide better alternatives. Stimufend is a therapeutic drug designed to assist cancer patients in addressing neutropenia. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company that specializes in pharmaceuticals, medical technologies, and nutrition products launched its first pegfilgrastim biosimilar, Stimufend in the U.S, which is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard, Stimufend launch marks the inaugural entry of the company into the U.S. biosimilars market for cancer care. This product provides healthcare professionals with a high-quality treatment alternative.

Pegfilgrastim Biosimilars Market Merger And Acquisition: Biocon Biologics Expands Biosimilar Footprint With Acquisition Of Viatris' Biosimilar Business

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, acquired Viatris ' biosimilar business for $3.34 billion. Through this acquisition, BBL would be able to direct-market more of its existing and upcoming biosimilars. To maintain customer service and facilitate a smooth transition to BBL, Viatris is expected to provide commercial and other transition services with this acquisition for an anticipated two-year term. ViatriInc.nc is a US-based pharmaceutical and healthcare corporation that has co-developed a biosimilar of pegfilgrastim.

Regional Analysis For The Global Pegfilgrastim Biosimilars Market

North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Pegfilgrastim Biosimilars Report Forecast And Analysis

Report Attribute	Details
Market Size Value In 2024	$1.75 billion
Revenue Forecast In 2033	$2.32 billion
Growth Rate	CAGR of 7.4% from 2024 to 2033
Base Year For Estimation	2023
Actual Estimates/Historical Data	2018-2023
Forecast Period	2024 - 2028 - 2033
Market Representation	Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered	1) By Application: Chemotherapy Treatment, Transplantation, Other Applications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
Regional Scope	Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Coherus BioSciences; Sandoz; Biocon/Mylan; Intas Biopharmaceuticals Ltd; Mundipharma GmbH; Dr. Reddy’s Laboratories; Pfizer Inc.; Emcure Pharmaceuticals; USV Private Limited; Apotex Pty Ltd; Kyowa Kirin Co. Ltd; Qilu Pharmaceutical; Gennova Biopharmaceuticals Limited; Lupin Limited; Coherus Biosciences Inc; Fresenius Kabi; Napp Pharmaceuticals; Boicon; Amega Biotech.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Pegfilgrastim Biosimilars Market Characteristics

3. Pegfilgrastim Biosimilars Market Trends And Strategies

4. Pegfilgrastim Biosimilars Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market

4.2. Ukraine-Russia War Impact On The Market

4.3. COVID-19 Impact On The Market

5. Global Pegfilgrastim Biosimilars Market Size and Growth

5.1. Global Pegfilgrastim Biosimilars Market Drivers and Restraints

5.1.1. Drivers Of The Market

5.1.2. Restraints Of The Market

5.2. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

5.3. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pegfilgrastim Biosimilars Market Segmentation

6.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Chemotherapy Treatment

Transplantation

Other Applications

6.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Mail-Order Pharmacies

7. Pegfilgrastim Biosimilars Market Regional And Country Analysis

7.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

7.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pegfilgrastim Biosimilars Market

8.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pegfilgrastim Biosimilars Market

9.1. China Pegfilgrastim Biosimilars Market Overview

9.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

9.3. China Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pegfilgrastim Biosimilars Market

10.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

10.2. India Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pegfilgrastim Biosimilars Market

11.1. Japan Pegfilgrastim Biosimilars Market Overview

11.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11.3. Japan Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pegfilgrastim Biosimilars Market

12.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12.2. Australia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pegfilgrastim Biosimilars Market

13.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13.2. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pegfilgrastim Biosimilars Market

14.1. South Korea Pegfilgrastim Biosimilars Market Overview

14.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14.3. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pegfilgrastim Biosimilars Market

15.1. Western Europe Pegfilgrastim Biosimilars Market Overview

15.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15.3. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pegfilgrastim Biosimilars Market

16.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16.2. UK Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pegfilgrastim Biosimilars Market

17.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17.2. Germany Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pegfilgrastim Biosimilars Market

18.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18.2. France Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pegfilgrastim Biosimilars Market

19.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19.2. Italy Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pegfilgrastim Biosimilars Market

20.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20.2. Spain Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pegfilgrastim Biosimilars Market

21.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

21.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pegfilgrastim Biosimilars Market

22.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22.2. Russia Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pegfilgrastim Biosimilars Market

23.1. North America Pegfilgrastim Biosimilars Market Overview

23.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23.3. North America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pegfilgrastim Biosimilars Market

24.1. USA Pegfilgrastim Biosimilars Market Overview

24.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24.3. USA Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pegfilgrastim Biosimilars Market

25.1. Canada Pegfilgrastim Biosimilars Market Overview

25.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25.3. Canada Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pegfilgrastim Biosimilars Market

26.1. South America Pegfilgrastim Biosimilars Market Overview

26.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pegfilgrastim Biosimilars Market

27.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27.2. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pegfilgrastim Biosimilars Market

28.1. Middle East Pegfilgrastim Biosimilars Market Overview

28.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pegfilgrastim Biosimilars Market

29.1. Africa Pegfilgrastim Biosimilars Market Overview

29.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

30.1. Pegfilgrastim Biosimilars Market Competitive Landscape

30.2. Pegfilgrastim Biosimilars Market Company Profiles

30.2.1. Coherus BioSciences

30.2.1.1. Overview

30.2.1.2. Products and Services

30.2.1.3. Strategy

30.2.1.4. Financial Performance

30.2.2. Sandoz

30.2.2.1. Overview

30.2.2.2. Products and Services

30.2.2.3. Strategy

30.2.2.4. Financial Performance

30.2.3. Biocon/Mylan

30.2.3.1. Overview

30.2.3.2. Products and Services

30.2.3.3. Strategy

30.2.3.4. Financial Performance

30.2.4. Intas Biopharmaceuticals Ltd

30.2.4.1. Overview

30.2.4.2. Products and Services

30.2.4.3. Strategy

30.2.4.4. Financial Performance

30.2.5. Mundipharma GmbH

30.2.5.1. Overview

30.2.5.2. Products and Services

30.2.5.3. Strategy

30.2.5.4. Financial Performance

31. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

31.1. Dr. Reddy’s Laboratories

31.2. Pfizer Inc.

31.3. Emcure Pharmaceuticals

31.4. USV Private Limited

31.5. Apotex Pty Ltd

31.6. Kyowa Kirin Co. Ltd

31.7. Qilu Pharmaceutical

31.8. Gennova Biopharmaceuticals Limited

31.9. Lupin Limited

31.10. Coherus Biosciences Inc

31.11. Fresenius Kabi

31.12. Napp Pharmaceuticals

31.13. Boicon

31.14. Amega Biotech.

31.15. Glenmark Pharmaceuticals Ltd

32. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking

33. Global Pegfilgrastim Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

35. Pegfilgrastim Biosimilars Market Future Outlook and Potential Analysis

35.1 Pegfilgrastim Biosimilars Market In 2028 - Countries Offering Most New Opportunities

35.2 Pegfilgrastim Biosimilars Market In 2028 - Segments Offering Most New Opportunities

35.3 Pegfilgrastim Biosimilars Market In 2028 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2018-2023, $ Billion

Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 8: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 9: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 10: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 11: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 12: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 13: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 14: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 15: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 16: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 17: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 18: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 19: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 20: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 21: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 22: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 23: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 24: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 25: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 26: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 27: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 28: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 29: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 30: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 31: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 32: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 33: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 34: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 35: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 36: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 37: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 38: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 39: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 40: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 41: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 42: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 43: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 44: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 45: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 46: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 47: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 48: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 49: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 50: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Table 51: Coherus BioSciences Financial Performance

Table 52: Sandoz Financial Performance

Table 53: Biocon/Mylan Financial Performance

Table 54: Intas Biopharmaceuticals Ltd Financial Performance

Table 55: Mundipharma GmbH Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2018-2023, $ Billion

Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion

Figure 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 5: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 6: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 7: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 8: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 9: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 10: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 11: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 12: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 13: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 14: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 15: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 16: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 17: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 18: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 19: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 20: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 21: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 22: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 23: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 24: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 25: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 26: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 27: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 28: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 29: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 30: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 31: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 32: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 33: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 34: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 35: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 36: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 37: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 38: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 39: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 40: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 41: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 42: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 43: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 44: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 45: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 46: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 47: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 48: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 49: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 50: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Figure 51: Coherus BioSciences Financial Performance

Figure 52: Sandoz Financial Performance

Figure 53: Biocon/Mylan Financial Performance

Figure 54: Intas Biopharmaceuticals Ltd Financial Performance

Figure 55: Mundipharma GmbH Financial Performance

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Trastuzumab Biosimilars Global Market Report 2024 – By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Rituximab Biosimilars Global Market Report 2024 – By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), By Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Mail Order) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilar Hormones Global Market Report 2024 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024 – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030

View Report

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies - Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the pegfilgrastim biosimilars market?

How will the pegfilgrastim biosimilars market drivers and restraints affect the pegfilgrastim biosimilars market dynamics? What forces will shape the pegfilgrastim biosimilars industry going forward?

The pegfilgrastim biosimilars market major growth driver - Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market. For further insights on the pegfilgrastim biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the pegfilgrastim biosimilars market?

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical r&d expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs. The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, aging population, increasing number of approvals, and targets and incentives . Major trends in the forecast period include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in r&d activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on m&a growth strategies to expand the customer base and their geographic markets, and increasing focus towards the production of biosimilars for neutropenia treatment to improve revenues and product offerings. For further insights on the pegfilgrastim biosimilars market, request a sample here

How is the pegfilgrastim biosimilars market segmented?

The pegfilgrastim biosimilars market is segmented
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies For further insights on the pegfilgrastim biosimilars market, request a sample here

Which region has the largest share of the pegfilgrastim biosimilars market? What are the other regions covered in the report?

North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the pegfilgrastim biosimilars market, request a sample here.

Who are the major players in the pegfilgrastim biosimilars market?

What are the key trends in the pegfilgrastim biosimilars market?

Major trend in the pegfilgrastim biosimilars market - Strategic Collaborations Fueling New Launches In The Pegfilgrastim Biosimilar Market. For further insights on the pegfilgrastim biosimilars market, request a sample here.

What are the major opportunities in the pegfilgrastim biosimilars market? What are the strategies for the pegfilgrastim biosimilars market?

For detailed insights on the major opportunities and strategies in the pegfilgrastim biosimilars market, request a sample here.

How does the pegfilgrastim biosimilars market relate to the overall economy and other similar markets?

For detailed insights on pegfilgrastim biosimilars market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the pegfilgrastim biosimilars industry?

For detailed insights on the mergers and acquisitions in the pegfilgrastim biosimilars industry, request a sample here.

What are the key dynamics influencing the pegfilgrastim biosimilars market growth? SWOT analysis of the pegfilgrastim biosimilars market.

For detailed insights on the key dynamics influencing the pegfilgrastim biosimilars market growth and SWOT analysis of the pegfilgrastim biosimilars industry, request a sample here.